SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-23-117180
Filing Date
2023-11-13
Accepted
2023-11-13 15:59:57
Documents
5
Period of Report
2023-12-13

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm2330482-1_def14a.htm DEF 14A 900804
2 GRAPHIC lg_vynetherapeutics-4clr.jpg GRAPHIC 15469
3 GRAPHIC sg_daviddonzalski-bwlr.jpg GRAPHIC 5451
4 GRAPHIC px_23page01-bw.jpg GRAPHIC 252547
5 GRAPHIC px_23page02-bw.jpg GRAPHIC 155150
  Complete submission text file 0001104659-23-117180.txt   1435299
Mailing Address 685 ROUTE 202/206 N., SUITE 301 BRIDGEWATER NJ 08807
Business Address 685 ROUTE 202/206 N., SUITE 301 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

IRS No.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38356 | Film No.: 231398362
SIC: 2834 Pharmaceutical Preparations